Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeliha Birsin

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Molecular and Clinical Oncology|March 13, 2026
Unmasking intratumoral heterogeneity: Postoperative revelation of subclonal divergence in <i>de novo</i> metastatic HR-positive/HER2-negative breast cancer: A case reportZeliha Birsin, Emir Çerme, Ceyda Sönmez Wetherilt, et al.
Journal of Clinical Neuromuscular Disease|June 2, 2026
Neuroimmune Crosstalk: Peripheral Nervous System Disorders After Immune Checkpoint InhibitorsAyşegül Gündüz, Merve İriş, Zeliha Birsin, et al.
Future Oncology (London, England)|December 30, 2025
Stage II colon cancer: does ChatGPT recommend more intensive adjuvant therapy? A comparison with MDT decisionsZeliha Birsin, Seda Jeral, Selin Cebeci, et al.
Journal of Clinical Medicine|September 27, 2025
Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone MetastasesVali Aliyev, Murad Guliyev, Murat Günaltılı, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 6, 2026
Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)Emir Cerme, Murad Guliyev, Vali Aliyev, et al.
Medicine|April 10, 2026
Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort studyMurat Günaltili, Murad Guliyev, Zeliha Birsin, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 16, 2026
Co-reported respiratory adverse events in trastuzumab deruxtecan-associated interstitial lung disease: A pharmacovigilance analysis of the FAERS databaseSeda Jeral Evinç, Çağla Eyüpler Akmercan, Zeliha Birsin, et al.
Current Medical Research and Opinion|June 8, 2026
Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancerZeliha Birsin, Vali Aliyev, Selin Cebeci, et al.
Annals of Hematology|September 9, 2025
Is splenectomy one of the contributory factors to pulmonary hypertension? An analysis of splenectomized hemolytic anemia and immune thrombocytopenia patientsZeliha Birsin, Ayşe Salihoğlu, Kardelen Ohtaroğlu Tokdil, et al.
Asia-Pacific Journal of Clinical Oncology|June 22, 2026
Comparative Real-World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance StudySeda Jeral Evinç, Çağla Eyüpler Akmercan, Zeliha Birsin, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Molecular and Clinical Oncology|March 13, 2026
Unmasking intratumoral heterogeneity: Postoperative revelation of subclonal divergence in <i>de novo</i> metastatic HR-positive/HER2-negative breast cancer: A case reportZeliha Birsin, Emir Çerme, Ceyda Sönmez Wetherilt, et al.
Journal of Clinical Neuromuscular Disease|June 2, 2026
Neuroimmune Crosstalk: Peripheral Nervous System Disorders After Immune Checkpoint InhibitorsAyşegül Gündüz, Merve İriş, Zeliha Birsin, et al.
Future Oncology (London, England)|December 30, 2025
Stage II colon cancer: does ChatGPT recommend more intensive adjuvant therapy? A comparison with MDT decisionsZeliha Birsin, Seda Jeral, Selin Cebeci, et al.
Journal of Clinical Medicine|September 27, 2025
Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone MetastasesVali Aliyev, Murad Guliyev, Murat Günaltılı, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 6, 2026
Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)Emir Cerme, Murad Guliyev, Vali Aliyev, et al.
Medicine|April 10, 2026
Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort studyMurat Günaltili, Murad Guliyev, Zeliha Birsin, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 16, 2026
Co-reported respiratory adverse events in trastuzumab deruxtecan-associated interstitial lung disease: A pharmacovigilance analysis of the FAERS databaseSeda Jeral Evinç, Çağla Eyüpler Akmercan, Zeliha Birsin, et al.
Current Medical Research and Opinion|June 8, 2026
Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancerZeliha Birsin, Vali Aliyev, Selin Cebeci, et al.
Annals of Hematology|September 9, 2025
Is splenectomy one of the contributory factors to pulmonary hypertension? An analysis of splenectomized hemolytic anemia and immune thrombocytopenia patientsZeliha Birsin, Ayşe Salihoğlu, Kardelen Ohtaroğlu Tokdil, et al.
Asia-Pacific Journal of Clinical Oncology|June 22, 2026
Comparative Real-World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance StudySeda Jeral Evinç, Çağla Eyüpler Akmercan, Zeliha Birsin, et al.
Pageof 2